Document is current
Any future updates will be listed below
-
Authors
Sánchez-Garrido, Miguel A. https://orcid.org/0000-0002-1010-5012
Serrano-López, Víctor
Ruiz-Pino, Francisco
Vázquez, María Jesús
Rodríguez-Martín, Andrea
Torres, Encarnación
Velasco, Inmaculada
Rodríguez, Ana Belén
Chicano-Gálvez, Eduardo
Mora-Ortiz, Marina https://orcid.org/0000-0002-6662-2932
Ohlsson, Claes https://orcid.org/0000-0002-9633-2805
Poutanen, Matti
Pinilla, Leonor
Gaytán, Francisco
Douros, Jonathan D.
Yang, Bin
Müller, Timo D.
DiMarchi, Richard D. https://orcid.org/0000-0003-0220-4085
Tschöp, Matthias H. https://orcid.org/0000-0002-4744-371X
Finan, Brian
Tena-Sempere, Manuel https://orcid.org/0000-0002-4741-5567
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (BFU2017-83934-P, PID2020-118660GB-I00)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PIE14-00005)
- License Information
-
More Information
Article History
Received: 12 October 2023
Accepted: 25 September 2024
First Online: 1 October 2024
Competing interests
: B.F., J.D.D., and B.Y. are former employees of Novo Nordisk. T.D.M. received funding from Novo Nordisk and speaking fees within the last 3 years from Novo Nordisk, Eli Lilly, Astra Zeneca, and Berlin Chemie AG. M.H.T. is a member of the SAB of ERX Pharmaceuticals, Inc. (last SAB meeting in 2019). Since 2018, he has served as the CSO and CEO of Helmholtz Munich (an academic research center with ca. 2500 scientists and staff). Helmholtz Munich is involved in numerous collaborations with a multitude of companies and institutions, worldwide. Cooperation, at times, involves research funding and includes (but are not limited to) interactions with e.g., Novo Nordisk, Boehringer Ingelheim, Roche Diagnostics, Arbormed, SCG Cell Therapy, and others. None of the above funding sources were involved in the preparation of this paper. M.T.S. has participated in the last 3 years in projects from Novo Nordisk and collaborated via grant agreements with the company Oxo-Life Ltd. (Barcelona, Spain), addressing therapeutic strategies for PCOS, although no connection exists between these projects/agreements and the present work. The rest of the authors have no conflict of interest to disclose in relation to the contents of this work.
